Company Introduction

Cellid Co.,Ltd. leads development of anti-cancer immunotherapy.

History

CELLID HISTORY
2021
2020
  • COVID-19 Vaccine IND Approved
  • Completed construction of Seongnam GMP Center
  • Completed phase-1 clinical trial on BVAC-B
  • Received approval on phase-1 clinical trial on BVAC-P
2019
  • Signed a contract on Seongnam SK V1 Tower
  • Listed in KOSDAQ (February 20)
2018
  • Signed a contract on general industrial complex in Magok
  • Won 'Grand Prize for Bio Field' in 4th Korean Company Contest hosted by Moneytoday
  • Developed phase-2 clinical trial on BVAC-C : Selected as Health and Medical Service Technology R&D Project by Ministry of Health and Welfare
  • Received approval on phase-1 clinical trial on BVAC-B
2017
  • Received approval on phase-2 a clinical trial on BVAC-C
  • Developed phase-1 clinical trial on BVAC-B, developed BVAC non-clinically : Selected as Research and Business Technology Development Project by Ministry of Trade, Industry and Energy
2016
  • Completed development of original CeliVax technology
  • Applied a patent right for CeliVax
  • Developed new convergent-type antigen : Selected as Bio/Medical Technology Development Project by Ministry of Science and ICT
  • Received approval on phase-1 clinical trial on BVAC-C
  • Developed phase-1 clinical trial on BVAC-C : Selected as Technical Innovative Business Investment Project by Ministry of SMEs and Startups
2015
  • Developed BVAC-B : Selected as Technical Innovation Business Investment Project by Ministry of SMEs and Startups
2014
  • BVAC-C License Out
  • Developed BVAC-C non-clinically : Selected as Advanced Medical Technology Development Project by Ministry of Health and Welfare
  • Secured a patent ownership for CeliVax
  • Established affiliate research center
  • Received venture certificate
2007
  • Started development of original CeliVax technology
2006
  • Founded Cellid Co.,Ltd. (December 11st)